Skip to main content

Advertisement

SpringerLink
Log in

Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor α

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

In this paper we investigated how the increase of human estrogen receptor alfa (ERα) gene expression may affect breast, osteoblast and osteoclast cells. Increase of ERα expression was obtained by interfering with the activity of a negative transcription factor and by removing it with a short and powerful decoy oligonucleotide (RA4-3′) mimicking a region of distal promoter C of ERα gene. We provide evidence that this decoy was able to induce apoptosis in osteoclasts, but not in osteoblasts and in breast cancer cells, in an estrogen dependent manner. This effect was associated with increase of the levels of Caspase 3 and Fas receptor. Since ERα is important in the transcription of different genes and is involved in several pathological processes, including neoplastic and osteopenic diseases, our findings may be of relevance for a possible new therapeutical approach of such diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Song RXD, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003; 8: 55–60.

    Article  PubMed  Google Scholar 

  2. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81: 1535–1565.

    PubMed  Google Scholar 

  3. Lee YJ, Renaud RA, Friedrich TC, Gorski J. Estrogen causes cell death of estrogen receptor stably transfected cells via apoptosis. J Steroid Biochem & Mol Biol 1998; 67: 327–332.

    Google Scholar 

  4. Vaananen H.K. Mechanism of bone turnover. Ann Med 1993; 25: 353–359.

    PubMed  Google Scholar 

  5. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279–302.

    Article  PubMed  Google Scholar 

  6. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289: 1508–1514.

    Google Scholar 

  7. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57: 385–409.

    Article  PubMed  Google Scholar 

  8. Schulte CMS, Beelen DW. Bone loss following hematopoietic stem cell transplantation: A long-term follow-up. Blood 2004; 103: 3635–3643.

    Article  PubMed  Google Scholar 

  9. Riggs BL. The mechanisms of estrogen regulation of bone resorption. Journal of Clinical Investigation 2000; 106: 1203–1204.

    Google Scholar 

  10. Roodman GD. Advances in bone biology: The osteoclasts. Endocr Rev 1996; 17: 308–332.

    Article  PubMed  Google Scholar 

  11. Yang X, Karsenty G. Transcription factors in bone: Developmental and pathological aspects. Trends in Molecular Medicine 2002; 8: 340–345.

    Article  PubMed  Google Scholar 

  12. Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis: Mechanisms and treatment strategies. Curr Opin Rheumatol 2004; 16: 419–427.

    Article  PubMed  Google Scholar 

  13. Moreno JL, Kaczmarek M, Keegan AD, Tondravi M. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL. Blood 2003; 102: 1078–1086.

    Article  PubMed  Google Scholar 

  14. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. Journal of Experimental Medicine 1997; 186: 489–495.

    Article  PubMed  Google Scholar 

  15. Piva R, Gambari R. Transcription factor decoy (TFD) in breast cancer research and treatment. Technology in Cancer Research Treatment 2002; 1: 405–416.

    PubMed  Google Scholar 

  16. Morishita R. Perspective in progress of cardiovascular gene therapy. Journal of Pharmacological Science 2004; 95: 1–8.

    Article  Google Scholar 

  17. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nature Medicine 1997; 3: 894–899.

    Article  PubMed  Google Scholar 

  18. Tomita N, Kim JY, Gibbons GH, et al. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. International Journal of Molecular Medicine 2004; 13: 629–636.

    PubMed  Google Scholar 

  19. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: State of the art and future prospects. Blood1998; 92: 712–736.

    PubMed  Google Scholar 

  20. Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Cis element “decoy” against upstream promoter of the human estrogen receptor gene. Biochim Biophys Acta 2000; 1492: 560–567.

    PubMed  Google Scholar 

  21. Lambertini E, Penolazzi L, Aguiari G, et al. Osteoblastic differentiation induced by transcription factor decoy against estrogen receptor alpha gene. Biochemical & Biophysical Research Communication 2002; 292: 761–770.

    Google Scholar 

  22. Kos M, Reid G, Denger S, Gannon F. Minireview: Genomic organization of the human ERalpha gene promoter region. Molecular Endocrinology 2001; 15: 2057–2063.

    Article  PubMed  Google Scholar 

  23. Yoshida T, Eguchi H, Nakachi K, et al. Distinct mechanisms of loss of estrogen receptor gene expression in human breast cancer: Methylation of the gene and alteration of trans-acting factors. Carcinogenesis 2000; 21: 2193–2201.

    Article  PubMed  Google Scholar 

  24. Maeda K, Tsuda H, Hashiguchi Y, et al. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer. Human Pathology 2002; 33: 386–391.

    Article  PubMed  Google Scholar 

  25. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451–4458.

    Article  PubMed  Google Scholar 

  26. Winding B, Misander H., Hoegh-Andersen P, Brunner N, Foged NT. Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo. Breast Cancer Research & Treatment 2003; 78: 205–216.

    Google Scholar 

  27. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer. J Natl Cancer Inst 2003; 95: 1597–1608.

    PubMed  Google Scholar 

  28. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305–1308.

    PubMed  Google Scholar 

  29. Matsuzaki K, Katayama K, Takahashi Y, et al. Human osteoclast-like cells are formed from peripheral blood mononuclear cells in a coculture with SaOS-2 cells transfected with the parathyroid hormone (PTH)/PTH-related protein receptor gene. Endocrinology 1999; 140: 925–932.

    Article  PubMed  Google Scholar 

  30. Maurizi M, Binaglia L, Donti E, Ottaviani F, Paludetti G, Venti Donti G. Morphological and functional characteristics of human temporal-bone cell cultures. Cell & Tissue Research 1983; 229: 505–513.

    Google Scholar 

  31. Penolazzi L, Lambertini E, Borgatti M, et al. Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: Induction of apoptosis in human primary osteoclasts. Biochemical Pharmacology 2003; 66: 1189–1198.

    Article  PubMed  Google Scholar 

  32. Villanova I, Townsed PA, Uhlmann E, et al. Oligodeoxynucleotide targeted to the alphav gene inhibits alphav integrin synthesis, impairs osteoclast function, and activates intracellular signals to apoptosis. Journal of Bone & Mineral Research 1999; 14: 1867–1879.

    Google Scholar 

  33. Denizot F, Lang RJ. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Immunol Meth 1986; 22: 271–277.

    Article  Google Scholar 

  34. Fibach E, Bianchi N, Borgatti M, Prus E, Gambari R. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood 2003; 102: 1276–1281.

    Article  PubMed  Google Scholar 

  35. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Research 1983; 11: 1475–1489.

    PubMed  Google Scholar 

  36. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. Journal of Biological Chemistry 2004; 279: 13984–13992.

    Article  PubMed  Google Scholar 

  37. Harada S, Sampath TK, Aubin JE, Rodan GA. Osteogenic protein-1 up-regulation of the collagen X promoter activity is mediated by a MEF-2-like sequence and requires an adjacent AP-1 sequence. Molecular Endocrinology 1997; 11: 1832–1845.

    Article  PubMed  Google Scholar 

  38. Fox SB, Brown P, Han C, et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clinical Cancer Research 2004; 10: 3521–3527.

    PubMed  Google Scholar 

  39. van Noort M, Clevers H. TCF transcription factors, mediators of Wnt-signaling in development and cancer. Dev Biol 2002; 244: 1–8.

    Article  PubMed  Google Scholar 

  40. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827–837.

    Article  PubMed  Google Scholar 

  41. Sooy K, Demay MB. Transcriptional repression of the rat osteocalcin gene by deltaEF1. Endocrinology 2002; 143: 3370–3375.

    Article  PubMed  Google Scholar 

  42. Levenson AS, Jordan VC. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994; 51: 229–239.

    Article  PubMed  Google Scholar 

  43. Wu X, Pan G, McKenna MA, Zayzafoon M, Xiong WC, McDonald JM. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J Bone Miner Res 2005; 20: 107–116.

    PubMed  Google Scholar 

  44. Song RXD, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang JP, Santen RJ. Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17-β Estradiol. J Natl Cancer Inst 2001; 93: 1714–1723.

    Article  PubMed  Google Scholar 

  45. Igarashi K, Hirotani H, Woo JT, Stern PH. Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 2004; 35: 47–56.

    Article  PubMed  Google Scholar 

  46. Sudhoff H, Jung JY, Ebmeyer J, Faddis BT, Hildmann H, Chole RA. Zoledronic acid inhibits osteoclastogenesis in vitro and in a mouse model of inflammatory osteolysis. Ann Otol Rhinol Laryngol 2003; 112: 780–786.

    PubMed  Google Scholar 

  47. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9: 2643–2658.

    Article  PubMed  Google Scholar 

  48. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes and Development 2003; 17: 2205–2232.

    Article  PubMed  Google Scholar 

  49. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. American Journal of Medicine 2000; 108: 153–164.

    Article  PubMed  Google Scholar 

  50. Delmas PD, Meunier PJ. The management of Paget’s disease of bone. New England Journal of Medicine 1997; 336: 558–566.

    Article  PubMed  Google Scholar 

  51. Hurtado J, Esbrit P. Treatment of malignant hypercalcaemia. Expert Opin Pharmacother 2002; 3: 521–527.

    Article  PubMed  Google Scholar 

  52. Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. British Journal of Haematology 2001; 112: 36–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Ferrara University, Ferrara, Italy

    R. Piva, L. Penolazzi, E. Lambertini, S. Giordano & R. Gambari

  2. ER-GenTech, Ferrara University, Ferrara, Italy

    R. Gambari

  3. Interdisciplinary Center for the Study of Inflammation, Ferrara University, Ferrara, Italy

    R. Gambari

  4. Dipartimento di Biochimica e Biologia Molecolare, Università degli Studi di Ferrara, Via Fossato di Mortara n. 74, 44100, Ferrara, Italy

    R. Gambari

Authors
  1. R. Piva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Penolazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Lambertini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Gambari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Gambari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piva, R., Penolazzi, L., Lambertini, E. et al. Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor α. Apoptosis 10, 1079–1094 (2005). https://doi.org/10.1007/s10495-005-0618-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-005-0618-8

Keywords

Search

Navigation